Simdax (levosimendan; Orion/Tenax Therapeutics) Drug Analysis Report 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Simdax" drug pipelines has been added to ResearchAndMarkets.com's offering.

Simdax (levosimendan; Orion/Tenax Therapeutics) is a calcium-sensitizing agent indicated for the treatment of acute decompensated heart failure (ADHF) in situations where conventional therapy is not sufficient. It acts by binding to cardiac troponin C in a calcium-dependent manner. Its pharmacological effects include increased cardiac contractility mediated by calcium sensitization of troponin C, vasodilation based on the opening of potassium channels in the vasculature, and cardioprotection due to the opening of mitochondrial potassium channels in the cardiomyocytes.

Key Topics Covered:

1 Product Profiles

  • Simdax: Acute decompensated heart failure (ADHF)

List of Figures

Figure 1: Simdax for ADHF - SWOT analysis

Figure 2: The author's drug asment summary of Simdax for ADHF

Figure 3: The author's drug assessment summary of Simdax for ADHF

List of Tables

Table 1: Simdax drug profile

Table 2: Simdax Phase III data in ADHF

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4c7qt8/simdax?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs